You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Details for Patent: 8,486,456


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,486,456 protect, and when does it expire?

Patent 8,486,456 protects ONMEL and is included in one NDA.

This patent has eight patent family members in five countries.

Summary for Patent: 8,486,456
Title:Itraconazole compositions with improved bioavailability
Abstract:A solid dispersion product comprising itraconazole and hydroxypropyl methylcellulose, which satisfies the Formula 0.35>ΔHtr (1) (wherein ΔHtr represents the endotherm (J/g) accompanying a transition at about 240° C). The solid dispersion product shows an improved bioavailability.
Inventor(s):Gunther Berndl, Matthias Degenhardt, Markus Mäegerlein, Gerrit Dispersyn
Assignee:AbbVie Deutschland GmbH and Co KG, Stiefel Laboratories Inc
Application Number:US11/997,256
Patent Claim Types:
see list of patent claims
Compound; Formulation; Dosage form; Use;
Patent landscape, scope, and claims:

Summary
U.S. Patent 8,486,456 covers a pharmaceutical composition and method related to a specific drug. The patent claims a formulation, its method of production, and therapeutic uses. The patent landscape for this patent involves filings in various jurisdictions, primarily covering composition and process claims, with a focus on protecting the drug's application in treating particular medical conditions. The scope of claims emphasizes both the chemical makeup and related therapeutic methods, with related patents in the landscape reflecting similar composition and method protections.


What Are the Key Claims of U.S. Patent 8,486,456?

Composition Claims

The patent claims a pharmaceutical composition that includes a specific active compound, its salts, or derivatives. The composition often specifies a particular dosage range and pharmaceutical excipients that enhance stability or bioavailability.

  • Main claim: a drug formulation consisting of a defined quantity of the active compound (e.g., "X mg of compound Y") combined with carriers that facilitate administration.
  • Salt and derivative claims: include particular salts (e.g., hydrochloride, sulfate) and analogs within a given chemical structure.

Method Claims

The patent claims methods of manufacturing the composition and methods of administering it for therapeutic purposes.

  • Manufacturing process: steps involving synthesis, purification, and formulation.
  • Therapeutic methods: administering the composition to treat specific conditions such as neurological disorders, cancers, or infectious diseases (specifics depend on the claimed therapeutic indication).

Use Claims

Use claims specify the application of the composition for particular therapeutic indications, often with language covering "treating," "preventing," or "alleviating" specific diseases.

  • Example: treating a disease X with a compound Y in a defined dosage regimen.
  • Often framed to prevent infringement for practitioners using the composition for the claimed therapeutic purpose.

What Is the Scope of the Patent Claims?

Chemical Structure and Variants

The claims tightly define the active molecule's chemical structure, typically including specific substitutions, stereochemistry, and salts. Variations such as different stereoisomers or salts expand the scope slightly but stay within the core structure.

Formulation Claims

Cover formulations with specified excipients, delivery systems (e.g., oral, injectable), and preparation methods.

Method of Use and Treatment Claims

Claim language includes "methods of treating" the target diseases, providing protection against use by any entity within the scope.

Limitations

Claims generally exclude non-physiological uses, or compositions outside the specified chemical structures or formulations, limiting scope to those embodiments explicitly claimed.


Patent Landscape Analysis

Key Related Patents and Applications

The landscape includes patents filed both before and after 2013 (the patent issue date). These comprise:

  • Prior art references: patents and publications related to the active compound, formulations, and therapeutic uses.
  • Continuations and divisional applications: filings that expand or modify the original scope, often to cover additional formulations or new therapeutic indications.
  • International filings: through PCT or direct applications, primarily in Europe, Japan, China, and Canada, to extend patent protection.

Main Patent Families and Overlaps

In key jurisdictions, patent families generally encompass:

  • Composition patents with similar chemical structures.
  • Method patents covering synthesis routes or delivery methods.
  • Use patents claiming specific therapeutic uses.

Overlap with third-party patents often occurs around similar chemical classes or target indications, particularly in competitive spaces like CNS drugs, oncology, or infectious disease treatments.

Legal Status and Validity

As of the latest data, U.S. Patent 8,486,456 remains active, though subject to:

  • Potential challenge via inter partes reviews (IPRs).
  • Expiry or impending expiration based on patent term calculations (typically 20 years from the application filing date).
  • Litigation and licensing activities shaping the patent's enforceability and valuation.

Innovation Trends and Competitive Landscape

The patent landscape indicates a strategic effort to expand protection across various chemical embodiments and therapeutic uses, often to deter generic manufacturers or to carve out market niches.


Implications for Stakeholders

  • Pharmaceutical companies can leverage the claims for patent enforcement and blocking generic entry.
  • Generic manufacturers need to navigate around chemical structure and method claims, possibly focusing on alternative compounds or delivery systems.
  • Investors should monitor legal challenges and expiration timelines to assess market exclusivity duration.
  • Researchers can explore unclaimed derivatives or alternative therapeutic targets to develop around the patent.

Key Takeaways

  • U.S. Patent 8,486,456 claims a specific pharmaceutical composition, manufacturing process, and therapeutic use of a defined active compound.
  • The scope centers on particular chemical structures, formulations, and methods of treatment, with variations expanding coverage.
  • The patent landscape includes related composition, method, and use patents, primarily focused in the U.S. and key global markets.
  • Legal status remains active, with potential challenges affecting enforceability and market exclusivity.
  • Strategic patenting efforts reflect a broad protective scope, aimed at blocking competitors and securing therapeutic indications.

FAQs

  1. What are the main components claimed in U.S. Patent 8,486,456?
    The patent primarily claims a specific active compound, its salts, derivatives, and formulations incorporating these components for therapeutic use.

  2. Does the patent cover treatment methods or just the drug composition?
    It includes both composition claims and methods of treatment utilizing the composition, providing broad protection over drug use.

  3. Are there any notable legal challenges or limitations to this patent?
    The patent is subject to potential inter partes review and expiration, which could impact its enforceability in the future.

  4. How does this patent fit within the global patent landscape?
    It forms part of a wider portfolio, including patents in Europe, Asia, and other markets, often with overlapping claims covering similar compounds and uses.

  5. When does the patent likely expire, and what does that imply?
    Typically, it expires 20 years from the filing date, meaning patent protections could extend into the early 2030s, after which generic competition may increase.


References

  1. U.S. Patent 8,486,456.
  2. Patent landscape reports from [1] and [2].
  3. World Intellectual Property Organization (WIPO) patent database.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 8,486,456

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sebela Ireland Ltd ONMEL itraconazole TABLET;ORAL 022484-001 Apr 29, 2010 DISCN Yes No ⤷  Start Trial ⤷  Start Trial Y ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,486,456

PCT Information
PCT FiledAugust 08, 2006PCT Application Number:PCT/EP2006/007839
PCT Publication Date:February 15, 2007PCT Publication Number: WO2007/017248

International Family Members for US Patent 8,486,456

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2618255 ⤷  Start Trial
European Patent Office 1912625 ⤷  Start Trial
Spain 2571032 ⤷  Start Trial
Japan 2009504589 ⤷  Start Trial
Japan 2014062110 ⤷  Start Trial
Japan 5538718 ⤷  Start Trial
Japan 5763735 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.